Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462561 · ClinicalTrials.gov registry record · NA
Vascularized Composite Bladder Allograft Transplantation
A NA study of Neurogenic Bladder and Immunosuppression, sponsored by University of Southern California.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05462561: Recruiting NA study of Neurogenic Bladder and Immunosuppression, sponsored by University of Southern California.
NCT05462561 is a NA study of Neurogenic Bladder and Immunosuppression that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 5 participants, below the 93-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05462561, a NA study of Neurogenic Bladder and Immunosuppression, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 0 trial tests the feasibility, functionality, and sustainability of vascularized composite bladder allograft transplantation in treating patients with terminal bladder pathology. A vascularized bladder allograft transplantation may provide a more durable and better-tolerated alternative to standard urinary diversion, which employs bowel. A robotic surgical approach will be employed.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- PROCEDURE Robotic Vascularized Composite Bladder Allograft Transplantation
Study Locations (1)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2028-10-03 |
| Phase | NA |
What NCT05462561 shows while recruiting
NCT05462561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 93-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Neurogenic Bladder appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05462561 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05462561 about?
NCT05462561 is a clinical study titled "Vascularized Composite Bladder Allograft Transplantation". This phase 0 trial tests the feasibility, functionality, and sustainability of vascularized composite bladder allograft transplantation in treating patients with terminal bladder pathology. A vascularized bladder allograft transplantation may provide a more durable and better-tolerated alternative t...
What is the current status of trial NCT05462561?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2023-05-01. Estimated completion is 2028-10-03.
What conditions does trial NCT05462561 study?
This clinical trial studies the following conditions: Neurogenic Bladder, Immunosuppression, Bladder Dysfunction.
What interventions are being tested in trial NCT05462561?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Robotic Vascularized Composite Bladder Allograft Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT05462561?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462561 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05462561's enrollment target sits among peer trials
5 17th of 16 the lowest of 16 other Neurogenic Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurogenic Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life
RECRUITING · NA
-
Electrical Stimulation for Continence After Spinal Cord Injury
ACTIVE NOT RECRUITING · NA
-
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
COMPLETED · NA
-
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
COMPLETED · NA
-
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI